B
Bull
Bull · 25%BIOA
$4.73
Precio del escenario
$9.650
-0.412 (-4.27%)Al cierre
Loading chart…
- High
- 10.250
- Open
- 10.060
- VWAP
- 9.83
- Vol
- 452.19K
- Mkt Cap
- —
- Low
- 9.595
- Amount
- 4.45M
- EV/EBITDA, TTM
- -2.03
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its lead product is BGE-102, a structurally novel, orally available small molecule NLRP3 inhibitor with high potency and brain penetration. In preclinical obesity models, BGE-102 resulted in weight loss as both a monotherapy and in combination with a GLP-1R agonist. Its pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel APJ agonists for metabolic disorders. In preclinical obesity models, APJ agonism has demonstrated the ability to more than double the weight loss induced by a GLP-1R agonist while also restoring healthy body composition and improving muscle function.
AI analysis of BioAge Labs, Inc. (BIOA)
holdBioAge Labs (BIOA) is currently trading at $9.65, significantly below the analyst price targets of $21, indicating potential upside. However, the stock has an RSI of 35.58, suggesting it is oversold, and the recent 5-day change is only +1.79%, indicating limited short-term momentum. The main risk is the company’s substantial net loss of $26.09 million in Q2, which raises concerns about its profitability and future cash flow.
Métricas de valoración
The current forward P/E ratio for BioAge Labs, Inc. (BIOA) is 0.00, compared to its 5-year average forward P/E of -2.98.
Alphio AI Price Scenarios for BIOA
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding BIOA
Cronología de eventos
Noticias
7.508-19NewsfilterBioArctic and Mesenkia Enter Research Collaboration for Glioblastoma Treatment
- 9.508-19Newsfilter
BioArctic to Release Q2 2026 Report on August 26
9.508-06NASDAQ.COMBioAge Labs Reports Wider Net Loss in Q2 Despite Revenue Increase
9.508-05seekingalphaBioAge Labs Q2 Earnings Beat Expectations with Revenue Growth
9.507-31stocktwitsNovo Nordisk's Drug Trial Failure Shakes Market Confidence
BIOA FAQ — answered by Alphio AI
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its lead product is BGE-102, a structurally novel, orally available small molecule NLRP3 inhibitor with high potency and brain penetration. In preclinical obesity models, BGE-102 resulted in weight loss as both a monotherapy and in combination with a GLP-1R agonist. Its pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel APJ agonists for metabolic disorders. In preclinical obesity models, APJ agonism has demonstrated the ability to more than double the weight loss induced by a GLP-1R agonist while also restoring healthy body composition and improving muscle function. It operates in the Healthcare sector.
BioAge Labs (BIOA) is currently trading at $9.65, significantly below the analyst price targets of $21, indicating potential upside. However, the stock has an RSI of 35.58, suggesting it is oversold, and the recent 5-day change is only +1.79%, indicating limited short-term momentum. The main risk is the company’s substantial net loss of $26.09 million in Q2, which raises concerns about its profitability and future cash flow.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.